New FDA Initiatives Aim to Spur Innovation

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-08-02-2003, Volume 27, Issue 8

Manufacturers face challenges from FDA's plans to streamline the drug review and development processes aimed to spur innovation.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-08-02-2003
In a Digital Gold Rush, Data Integrity is Priceless
FDA Gets Its Arms Around Advanced Therapy Medicinal Products Early
Control Strategy: A Feedback-Feedforward ‘Controls Hub’ for Risk, Knowledge, and Product Lifecycle Management